Equity Profile

INSM

Insmed Incorporated

Health CareBiotechnology$23.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Insmed plays a crucial role in addressing unmet medical needs, particularly in rare diseases.

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue

While specific revenue estimates are not available, any reported revenue will be critical in assessing the company's growth trajectory.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In Q1 2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a positive surprise of 15.84%. However, the stock fell 23.41% the next day, indicating market disappointment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Insmed has shown volatility in its earnings history. The company has a low EPS beat rate, which may lead to cautious sentiment among investors.

Bull Case

If Insmed can demonstrate improved revenue growth and continued progress in its drug pipeline, it could restore investor confidence and drive the stock higher.

Bear Case

On the other hand, if the company fails to meet expectations or provides lackluster guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the reported EPS be this quarter?

Given the company's history of earnings surprises, the EPS figure will be crucial in determining market sentiment and stock movement.

How does management view revenue growth prospects?

Any insights into revenue growth will be pivotal for investors looking to understand the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for a significant revenue rebound based on recent drug pipeline developments.

Supporting Evidence

The options market is pricing a 21.56% move, indicating expectations for volatility that may not align with historical performance.

Insmed's recent EPS beat, despite a stock drop, suggests that the market may be overly pessimistic about future growth.

Key Risk

If the EPS comes in better than -$0.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly focused on profitability and revenue growth, making these thresholds critical for investor sentiment.

Bull Confirmed If

A reported EPS of -$0.50 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.90 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect notable volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations, history suggests a potential stock increase of around 16.33%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 1.98%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug pipeline progress and potential FDA approvals.
2Management's commentary on revenue growth and market expansion strategies.
3Insights into cost management and operational efficiency improvements.
4Guidance on future earnings expectations and market conditions.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue

While specific revenue estimates are not available, any reported revenue will be critical in assessing the company's growth trajectory.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Insmed has shown volatility in its earnings history. The company has a low EPS beat rate, which may lead to cautious sentiment among investors.

Bull Case

If Insmed can demonstrate improved revenue growth and continued progress in its drug pipeline, it could restore investor confidence and drive the stock higher.

Bear Case

On the other hand, if the company fails to meet expectations or provides lackluster guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the reported EPS be this quarter?

Given the company's history of earnings surprises, the EPS figure will be crucial in determining market sentiment and stock movement.

How does management view revenue growth prospects?

Any insights into revenue growth will be pivotal for investors looking to understand the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for a significant revenue rebound based on recent drug pipeline developments.

Supporting Evidence

The options market is pricing a 21.56% move, indicating expectations for volatility that may not align with historical performance.

Insmed's recent EPS beat, despite a stock drop, suggests that the market may be overly pessimistic about future growth.

Key Risk

If the EPS comes in better than -$0.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly focused on profitability and revenue growth, making these thresholds critical for investor sentiment.

Bull Confirmed If

A reported EPS of -$0.50 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.90 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect notable volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations, history suggests a potential stock increase of around 16.33%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 1.98%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug pipeline progress and potential FDA approvals.
2Management's commentary on revenue growth and market expansion strategies.
3Insights into cost management and operational efficiency improvements.
4Guidance on future earnings expectations and market conditions.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.